| Name | Title | Contact Details |
|---|
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.
Fayette Companies is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Peoria, IL. To find more information about Fayette Companies, please visit www.fayettecompanies.org
Danisco Venture (www.danisco.com/venture) is a corporate venture unit within Danisco A/S - one of the world's largest producers of ingredients for the food and feed industry.
Physicians Programs Inc is a Flint, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Preferred Health Professionals is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.